Changyuan Wei
- Topics
- Breast Cancer Treatment Studies (8 papers)Cancer Cells and Metastasis (5 papers)HER2/EGFR in Cancer Research (3 papers)
In The Last Decade
Changyuan Wei
22 papers receiving 427 citations
Peers
Comparison fields: 5 of 83
- Cancer Research 165
- Molecular Biology 154
- Oncology 151
- Surgery 92
- Pathology and Forensic Medicine 65
Countries citing papers authored by Changyuan Wei
This map shows the geographic impact of Changyuan Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changyuan Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changyuan Wei more than expected).
Fields of papers citing papers by Changyuan Wei
This network shows the impact of papers produced by Changyuan Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changyuan Wei. The network helps show where Changyuan Wei may publish in the future.
Co-authorship network of co-authors of Changyuan Wei
This figure shows the co-authorship network connecting the top 25 collaborators of Changyuan Wei. A scholar is included among the top collaborators of Changyuan Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changyuan Wei. Changyuan Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 10 | |
| 4 | 14 | |
| 5 | 8 | |
| 6 | 38 | |
| 7 | 6 | |
| 8 | 42 | |
| 9 | 4 | |
| 10 | [Effects of FBI-1 silencing on proliferation and apoptosis of triple-negative breast cancer cell line MDA-MB-231]. | 4 |
| 11 | 8 | |
| 12 | 8 | |
| 13 | 3 | |
| 14 | Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. | 50 |
| 15 | 39 | |
| 16 | Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients. | 14 |
| 17 | Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. | 47 |
| 18 | 16 | |
| 19 | 43 | |
| 20 | 35 |
About Changyuan Wei
Changyuan Wei is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 24 papers that have together received 436 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (8 papers), Cancer Cells and Metastasis (5 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Cancer Research (165 citations), Geriatrics and Gerontology (23 citations) and Oncology (151 citations). Changyuan Wei has collaborated with scholars based in China and Taiwan. Frequent co-authors include Qinghong Qin, Weiping Yang, Qinguo Mo, Qixing Tan, Bin Lian, Tai‐Wai Chin, Jinbo Huang, Xiao Dong Zhu, Jie He and Miao Liu. Their work appears in journals such as PLoS ONE, Scientific Reports and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.